Manuscripts and Publications

Filters: Author is Han, Meilan K  [Clear All Filters]
2018
J Wells M, Parker MM, Oster RA, Bowler RP, Dransfield MT, Bhatt SP, Cho MH, Kim V, Curtis JL, Martinez FJ et al..  2018.  Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene.. JCI Insight. 3(22)
Pirozzi CS, Gu T, Quibrera PM, Carretta EE, Han MK, Murray S, Cooper CB, Tashkin DP, Kleerup EC, Barjaktarevic I et al..  2018.  Heterogeneous burden of lung disease in smokers with borderline airflow obstruction.. Respir Res. 19(1):223.
Smith BM, Traboulsi H, Austin JHM, Manichaikul A, Hoffman EA, Bleecker ER, Cardoso WV, Cooper C, Couper DJ, Dashnaw SM et al..  2018.  Human airway branch variation and chronic obstructive pulmonary disease.. Proc Natl Acad Sci U S A. 115(5):E974-E981.
Putcha N, Paul GG, Azar A, Wise RA, O'Neal WK, Dransfield MT, Woodruff PG, Curtis JL, Comellas AP, M Drummond B et al..  2018.  Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS.. PLoS One. 13(4):e0194924.
Morris MA, Jacobson SR, Kinney GL, Tashkin DP, Woodruff PG, Hoffman EA, Kanner RE, Cooper CB, M Drummond B, R Barr G et al..  2018.  Marijuana Use Associations with Pulmonary Symptoms and Function in Tobacco Smokers Enrolled in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS).. Chronic Obstr Pulm Dis. 5(1):46-56.
Labaki WW, Xia M, Murray S, Curtis JL, R Barr G, Bhatt SP, Bleecker ER, Hansel NN, Cooper CB, Dransfield MT et al..  2018.  NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.. Respir Med. 140:87-93.
Burkes RM, Gassett AJ, Ceppe AS, Anderson W, O'Neal WK, Woodruff PG, Krishnan JA, R Barr G, Han MK, Martinez FJ et al..  2018.  Rural Residence and Chronic Obstructive Pulmonary Disease Exacerbations. Analysis of the SPIROMICS Cohort.. Ann Am Thorac Soc. 15(7):808-816.
2019
Christenson SA, van den Berge M, Faiz A, Inkamp K, Bhakta N, Bonser LR, Zlock LT, Barjaktarevic IZ, R Barr G, Bleecker ER et al..  2019.  An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup.. J Clin Invest. 129(1):169-181.
Ghosh S, Anderson WH, Putcha N, Han MK, Curtis JL, Criner GJ, Dransfield MT, R Barr G, Krishnan JA, Lazarus SC et al..  2019.  Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS.. Ann Am Thorac Soc. 16(2):200-208.
Fawzy A, Putcha N, Aaron CP, Bowler RP, Comellas AP, Cooper CB, Dransfield MT, Han MK, Hoffman EA, Kanner RE et al..  2019.  Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study.. Chest. 155(3):519-527.
Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Iii RPaine, Bhatt SP, Bhakta NR et al..  2019.  Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.. Int J Chron Obstruct Pulmon Dis. 14:2927-2938.
Oelsner EC, Ortega VE, Smith BM, Nguyen JN, Manichaikul AW, Hoffman EA, Guo X, Taylor KD, Woodruff PG, Couper DJ et al..  2019.  A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography.. Am J Respir Crit Care Med. 200(6):721-731.
Arjomandi M, Zeng S, Barjaktarevic I, R Barr G, Bleecker ER, Bowler RP, Buhr RG, Criner GJ, Comellas AP, Cooper CB et al..  2019.  Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS.. Eur Respir J. 54(4)
J Wells M, Arenberg DA, Barjaktarevic I, Bhatt SP, Bowler RP, Christenson SA, Couper DJ, Dransfield MT, Han MK, Hoffman EA et al..  2019.  Safety and Tolerability of Comprehensive Research Bronchoscopy in Chronic Obstructive Pulmonary Disease. Results from the SPIROMICS Bronchoscopy Substudy.. Ann Am Thorac Soc. 16(4):439-446.
Labaki WW, Gu T, Murray S, Curtis JL, Yeomans L, Bowler RP, R Barr G, Comellas AP, Hansel NN, Cooper CB et al..  2019.  Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study.. Sci Rep. 9(1):11367.
Bin Cho H, Chae KJu, Jin GYong, Choi J, Lin CLong, Hoffman EA, Wenzel SE, Castro M, Fain SB, Jarjour NN et al..  2019.  Structural and Functional Features on Quantitative Chest Computed Tomography in the Korean Asian versus the White American Healthy Non-Smokers.. Korean J Radiol. 20(7):1236-1245.
Garudadri S, Woodruff PG, Han MK, Curtis JL, R Barr G, Bleecker ER, Bowler RP, Comellas A, Cooper CB, Criner G et al..  2019.  Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS.. Chest. 155(5):908-917.
2020
Galiatsatos P, Woo H, Paulin LM, Kind A, Putcha N, Gassett AJ, Cooper CB, Dransfield MT, Parekh TM, Oates GR et al..  2020.  The Association Between Neighborhood Socioeconomic Disadvantage and Chronic Obstructive Pulmonary Disease.. Int J Chron Obstruct Pulmon Dis. 15:981-993.
Smith BM, Kirby M, Hoffman EA, Kronmal RA, Aaron SD, Allen NB, Bertoni A, Coxson HO, Cooper C, Couper DJ et al..  2020.  Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults.. JAMA. 323(22):2268-2280.
Zhang WZ, Rice MC, Hoffman KL, Oromendia C, Barjaktarevic IZ, J Wells M, Hastie AT, Labaki WW, Cooper CB, Comellas AP et al..  2020.  Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort.. JCI Insight. 5(3)
Putcha N, Fawzy A, Matsui EC, Liu MC, Bowler RP, Woodruff PG, O'Neal WK, Comellas AP, Han MK, Dransfield MT et al..  2020.  Clinical Phenotypes of Atopy and Asthma in COPD: A Meta-analysis of SPIROMICS and COPDGene.. Chest. 158(6):2333-2345.
Kim V, Jeong S, Zhao H, Kesimer M, Boucher RC, J Wells M, Christenson SA, Han MK, Dransfield M, Paine R et al..  2020.  Current smoking with or without chronic bronchitis is independently associated with goblet cell hyperplasia in healthy smokers and COPD subjects.. Sci Rep. 10(1):20133.
Ortega VE, Li X, O'Neal WK, Lackey L, Ampleford E, Hawkins GA, Grayeski PJ, Laederach A, Barjaktarevic I, R Barr G et al..  2020.  The Effects of Rare Variants on Lung Function and Emphysema in SPIROMICS.. Am J Respir Crit Care Med. 201(5):540-554.
Zhang WZ, Oromendia C, Kikkers SAnn, Butler JJ, O'Beirne S, Kim K, O'Neal WK, Freeman CM, Christenson SA, Peters SP et al..  2020.  Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS.. Sci Rep. 10(1):10562.
Cooper CB, Paine R, Curtis JL, Kanner RE, Martinez CH, Meldrum CA, Bowler R, O'Neal W, Hoffman EA, Couper D et al..  2020.  Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort.. Int J Chron Obstruct Pulmon Dis. 15:1887-1898.

Pages